Uridine modulates monoclonal antibody charge heterogeneity in Chinese hamster ovary cell fed-batch cultures

Abstract

Background

Charge heterogeneity is one of the most critical quality attributes of antibodies, which has strong influence on drug’s biological activity and safety. Finding out the key components that affecting charge variants is of great significance for establishing a competitive culture process. In this study, we first illustrated uridine’s great impacts on antibody charge heterogeneity in CHO cell fed-batch cultures.

Results

Uridine was beneficial to cell growth and the maintenance of cell viability, which made IVCC increased by 50% and the final titer improved by 64%. However, uridine had great influences on mAb’s charge variants. In uridine added cultures, the acidic variant levels were about 9% lower than those in control cultures, while the basic variant levels were about 6% higher than those in control cultures. Further investigation found that the decrease of aggregates and glycated forms were responsible for the reduction of acidic variants. What’s more, uridine decreased the lysine variant levels.

Conclusions

Uridine’s addition to fed-batch promoted cell growth and the final titer, in the meanwhile, uridine decreased the acidic variants dramatically. Therefore, feeding uridine is an efficient way to control the generation of acidic charge variants in up-stream process. These findings provide new ideas and guidance for the control and optimization of antibody charge heterogeneity in culture process developments.

Keywords

Charge heterogeneity / Chinese hamster ovary cells / Medium components / Monoclonal antibody / Uridine

References

[1] Brorson K, Jia AY. Therapeutic monoclonal antibodies and consistent ends: terminal heterogeneity, detection, and impact on quality. Curr Opin Biotechnol, 2014, 30: 140-146.

[2] Chen F, Fan L, Wang J, Zhou Y, Ye Z, Zhao L, Tan W-S. Insight into the roles of hypoxanthine and thydimine on cultivating antibody-producing CHO cells: cell growth, antibody production and long-term stability. Appl Microbiol Biotechnol, 2011, 93: 169-178.

[3] Dillon T, . Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem, 2008, 283: 16206.

[4] Gandhi S, Ren D, Xiao G, Bondarenko P, Sloey C, Ricci MS, Krishnan S. Elucidation of degradants in acidic peak of cation exchange chromatography in an IgG1 monoclonal antibody formed on long-term storage in a liquid formulation. Pharm Res, 2012, 29: 209-224.

[5] Gramer MJ, . Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose. Biotechnol Bioeng, 2011, 108: 1591-1602.

[6] Haberger M, . Assessment of chemical modifications of sites in the CDRs of recombinant antibodies. mAbs, 2014, 6: 327.

[7] Hong JK, Lee SM, Kim KY, Lee GM. Effect of sodium butyrate on the assembly, charge variants, and galactosylation of antibody produced in recombinant Chinese hamster ovary cells. Appl Microbiol Biotechnol, 2014, 98: 5417-5425.

[8] Hossler P, . Cell culture media supplementation of bioflavonoids for the targeted reduction of acidic species charge variants on recombinant therapeutic proteins. Biotechnol Prog, 2015, 31: 1039-1052.

[9] Jayapal KP, Wlaschin KF, Hu WS, Yap MGS. Recombinant protein therapeutics from CHO cells—20 years and counting. Chem Eng Prog, 2007, 103: 40-47.

[10] Kaschak T, . Characterization of the basic charge variants of a human IgG1: effect of copper concentration in cell culture media. mAbs, 2011, 3: 577-583.

[11] Khawli LA, . Charge variants in IgG1: isolation, characterization, in vitro binding properties and pharmacokinetics in rats. mAbs, 2010, 2: 613-624.

[12] Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J. Heterogeneity of monoclonal antibodies. J Pharm Sci, 2008, 97: 2426-2447.

[13] Luo J, Zhang J, Ren D, Tsai WL, Li F, Amanullah A, Hudson T. Probing of C-terminal lysine variation in a recombinant monoclonal antibody production using Chinese hamster ovary cells with chemically defined media. Biotechnol Bioeng, 2012, 109: 2306-2315.

[14] Siemiatkoski J, Lyubarskaya Y, Houde D, Tep S, Mhatre R. A comparison of three techniques for quantitative carbohydrate analysis used in characterization of therapeutic antibodies. Carbohydr Res, 2006, 341: 410-419.

[15] Sun Y-T, Zhao L, Ye Z, Fan L, Liu X-P, Tan W-S. Development of a fed-batch cultivation for antibody-producing cells based on combined feeding strategy of glucose and galactose. Biochem Eng J, 2013, 81: 126-135.

[16] Takagi Y, Kikuchi T, Wada R, Omasa T. The enhancement of antibody concentration and achievement of high cell density CHO cell cultivation by adding nucleoside. Cytotechnology, 2017, 69: 511-521.

[17] Wei B, Berning K, Quan C, Zhang YT. Glycation of antibodies: modification, methods and potential effects on biological functions. mAbs, 2017, 9: 586-594.

[18] Yan B, . Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain. J Pharm Sci, 2009, 98: 3509-3521.

[19] Yang JM, . Investigation of the correlation between charge and glycosylation of IgG1 variants by liquid chromatography–mass spectrometry. Anal Biochem, 2014, 448: 82-91.

[20] Yoon SK, Kim SH, Lee GM. Effect of low culture temperature on specific productivity and transcription level of anti-4–1BB antibody in recombinant Chinese hamster ovary cells. Biotechnol Prog, 2003, 19: 1383-1386.

[21] Zhang T, Bourret J, Cano T. Isolation and characterization of therapeutic antibody charge variants using cation exchange displacement chromatography. J Chromatogr A, 2011, 1218: 5079-5086.

[22] Zhang X, Tang H, Sun YT, Liu X, Tan WS, Fan L. Elucidating the effects of arginine and lysine on a monoclonal antibody C-terminal lysine variation in CHO cell cultures. Appl Microbiol Biotechnol, 2015, 99: 6643-6652.